HLA-C and KIR combined genotype as new response marker for HBeAg-positive chronic hepatitis B patients treated with interferon-based combination therapy

Journal of Viral Hepatitis

Volumn 23, Issue 8, 2016, Pages 652-659

  Stelma, F ^a   Jansen, L ^a   Sinnige, M J ^a   van Dort, K A ^a   Takkenberg, R B ^a   Janssen, H L A ^b,c   Reesink, H W ^a   Kootstra, N A ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

combination therapy; Hepatitis B; HLA C; KIR; NK cell; peg interferon alfa

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; BIOLOGICAL MARKER; HEPATITIS B(E) ANTIGEN; HLA C ANTIGEN; HLA C2 ANTIGEN; KIR PROTEIN; KIR2DL1 PROTEIN; MEMBRANE RECEPTOR; PEGINTERFERON ALPHA2A; UNCLASSIFIED DRUG;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHRONIC HEPATITIS B; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; GENE; GENOTYPE; HLA C GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; KIR GENE; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PATIENT SELECTION; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; PROTEIN BINDING; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84978661355     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12525     Document Type: Article

References (34)

1. Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine 2012; 30: 2212–2219.
2. Beasley RP. Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer 1988; 61: 1942–1956.
3. Thimme R, Dandri M. Dissecting the divergent effects of interferon-alpha on immune cells: time to rethink combination therapy in chronic hepatitis B? J Hepatol 2013; 58: 205–209.
4. Takkenberg RB, Jansen L, de Niet A et al. Baseline hepatitis B surface antigen (HBsAg) as predictor of sustained HBsAg loss in chronic hepatitis B patients treated with peginterferon alfa-2a and adefovir. Antivir Ther 2013; 18: 895–904.
5. Marcellin P, Ahn SH, Ma X et al. 193 HBsAg loss with Tenofovir Disoproxil Fumarate (TDF) plus Peginterferon alfa-2a (PEG) in Chronic Hepatitis B (CHB): results of a global randomized controlled trial. Hepatology 2014; 60: 294A.
6. Maini MK, Boni C, Ogg GS et al. Direct ex vivo analysis of hepatitis B virus-specific CD8(+) T cells associated with the control of infection. Gastroenterology 1999; 117: 1386–1396.
7. Stelma F, de Niet A, Tempelmans Plat-Sinnige MJ et al. Natural Killer Cell Characteristics in Patients With Chronic Hepatitis B Virus (HBV) Infection Are Associated With HBV Surface Antigen Clearance After Combination Treatment With Pegylated Interferon Alfa-2a and Adefovir. J Infect Dis 2015; 212: 1042–1051.
8. Micco L, Peppa D, Loggi E et al. Differential boosting of innate and adaptive antiviral responses during pegylated-interferon-alpha therapy of chronic hepatitis B. J Hepatol 2013; 58: 225–233.
9. Blais ME, Dong T, Rowland-Jones S. HLA-C as a mediator of natural killer and T-cell activation: Spectator or key player? Immunology 2011; 133: 1–7.
10. Zhang Y, Zhang H, Huang Y, Sun R, Liu R, Wei J. Human leukocyte antigen (HLA)-C polymorphisms are associated with a decreased risk of rheumatoid arthritis. Mol Biol Rep 2014; 41: 4103–4108.
11. Khakoo SI, Thio CL, Martin MP et al. HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science 2004; 305: 872–874.
12. Suppiah V, Gaudieri S, Armstrong NJ et al. IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European Cohort: a cross-sectional study. PLoS Med 2011; 8: e1001092.
13. Hu Z, Liu Y, Zhai X et al. New loci associated with chronic hepatitis B virus infection in Han Chinese. Nat Genet 2013; 45: 1499–1503.
14. Jiang D, Ma X, Yu H et al. Genetic variants in five novel loci including CFB and CD40 predispose to chronic hepatitis B. Hepatology 2015; 62: 118–128.
15. EASL clinical practice guidelines. Management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167–185.
16. Jansen L, de Niet A, Stelma F et al. HBsAg loss in patients treated with peginterferon alfa-2a and adefovir is associated with SLC16A9 gene variation and lower plasma carnitine levels. J Hepatol 2014; 61: 730–737.
17. Johnson AD, Handsaker RE, Pulit SL, Nizzari MM, O'Donnell CJ, De Bakker PIW. SNAP: a web-based tool for identification and annotation of proxy SNPs using HapMap. Bioinformatics 2008; 24: 2938–2939.
18. The International HapMap Consortium. A second generation human haplotype map of over 3.1 million SNPs. Nature 2007; 449: 851–861.
19. Dilthey A, Leslie S, Moutsianas L et al. Multi-Population Classical HLA Type Imputation. PLoS Comput Biol 2013; 9: e1002877.
20. Kulkarni S, Martin MP, Carrington M. KIR genotyping by multiplex PCR-SSP. Methods Mol Biol 2010; 612: 365–375.
21. Mandelboim O, Reyburn HT, Pazmany L, Colonna M, Borsellino G, Strominger JL. Protection from Lysis by Natural Killer Cells of Group 1 and 2 Specificity Is Mediated by Residue 80 in Human Histocompatibility Leukocyte Antigen C Alleles and Also Occurs with Empty Major Histocompatibility Complex Molecules. J Exp Med 1996; 184: 913–922.
22. David G, Djaoud Z, Willem C et al. Large spectrum of HLA-C recognition by killer Ig-like receptor (KIR)2DL2 and KIR2DL3 and restricted C1 specificity of KIR2DS2: dominant impact of KIR2DL2/KIR2DS2 on KIR2D NK cell repertoire formation. J Immunol 2013; 191: 4778–4788.
23. Puppo F, Scudeletti M, Indiveri F, Ferrone S. Serum HLA class I antigens: markers and modulators of an immune response? Immunol Today 1995; 16: 124–127.
24. Aulitzky WE, Grosse-Wilde H, Westhoff U et al. Enhanced serum levels of soluble HLA class I molecules are induced by treatment with recombinant interferon-gamma (IFN-gamma). Clin Exp Immunol 1991; 86: 236–239.
25. Kim S, Poursine-Laurent J, Truscott SM et al. Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature 2005; 436: 709–713.
26. Anfossi N, André P, Guia S et al. Human NK cell education by inhibitory receptors for MHC class I. Immunity 2006; 25: 331–342.
27. Buster EHCJ, Hansen BE, Lau GKK et al. Factors That Predict Response of Patients With Hepatitis B e Antigen-Positive Chronic Hepatitis B to Peginterferon-Alfa. Gastroenterology 2009; 137: 2002–2009.
28. de Niet A, Jansen L, Zaaijer HL et al. Experimental HBsAg/anti-HBs complex assay for prediction of HBeAg loss in chronic hepatitis B patients treated with pegylated interferon and adefovir. Antivir Ther 2014; 19: 259–267.
29. Sonneveld MJ, Hansen BE, Piratvisuth T et al. Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels. Hepatology 2013; 58: 872–880.
30. Marcellin P, Bonino F, Lau GKK et al. Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alfa-2a. Gastroenterology 2009; 136: 2169–2179. e4.
31. Lampertico P, Viganò M, Cheroni C et al. IL28B polymorphisms predict interferon-related hepatitis B surface antigen seroclearance in genotype D hepatitis B e antigen-negative patients with chronic hepatitis B. Hepatology 2013; 57: 890–896.
32. Rijckborst V, Hansen BE, Cakaloglu Y et al. Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels. Hepatology 2010; 52: 454–461.
33. Brunetto MR, Marcellin P, Cherubini B et al. Response to peginterferon alfa-2a (40KD) in HBeAg-negative CHB: on-treatment kinetics of HBsAg serum levels vary by HBV genotype. J Hepatol 2013; 59: 1153–1159.
34. Moucari R, Mackiewicz V, Lada O et al. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology 2009; 49: 1151–1157.